PDCD1 and neoplasm: TGF-β is a master regulator of radiotherapy-induced anti-tumour immunity and inhibition of TGF-β with a pan-TGFb antibody has been shown to enhance immune responses, which were further enhanced by the addition of PD-1 inhibition.